5:14 PM
 | 
May 25, 2010
 |  BC Extra  |  Clinical News

Clobazam meets Phase III endpoint

H. Lundbeck A/S (CSE:LUN) said clobazam met the primary endpoint in a Phase III trial to treat Lennox-Gastaut...

Read the full 71 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >